Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712572 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
Electronic  Add to Basket



Italy Pharmaceuticals and Healthcare Report Q4 2008

Business Monitor International, Dec 2008, Pages: 65


  Description  
   Table of Contents   
   Companies Mentioned   
    
    
     
  Enquire before Buying   
  Send to a Friend   

Our Italy Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Italy's pharmaceuticals and healthcare industry.

The poor performance in the Italian market looks set to continue over the forecast period. Following low growth in 2005 and 2006, the market posted a decline in 2007. Between 2007 and 2012 the compound annual growth rate (CAGR) should be just 1.85% in local currency terms, with the market reaching a value of EUR25.1bn (US$US$32.2bn). The first six months of 2008 seem to support this pessimistic prognosis, with market expenditure by the Italian National Health Service - the Servicio Sanitario Nazionale (SSN) - falling by 1.4% (year-on-year).

From 2006, the state has made a concerted effort to decrease prices through initiatives including increasing generic penetration, the introduction of new reference pricing and across-the-board price cuts. This had a significant impact on spending in 2007, the effects of which are being carried through into2008 with average price reductions of 6.9% y-o-y per pack in the first half.

As a result, most of Italy’s major pharmaceutical players have been looking to foreign markets to drive growth. In H108, Recordati saw sales on the domestic front fall 2.4%, which the company attributed to negative price effects. Sales on foreign markets, however, increased by 13.3% y-o-y and now account for close to 70% of total pharmaceutical sales.

Meanwhile, Italy has climbed off of the bottom of BMI’s business environment rankings for Q408, although that was mainly due to the deteriorating business environment rankings of Spain, which now props up the table. Italy hasn’t been helped by recent allegations of corruption at the Italian medicine agency AIFA. Director general Nell Martini has been suspended following a two-year investigation into the approval and subsequent granting of licences for a number of drugs.


Product samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

Serbia Pharmaceuticals and Healthcare Report Q1 2011

Italy Pharmaceuticals and Healthcare Report Q1 2011

Italy Pharmaceuticals and Healthcare Report Q4 2010

Kazakhstan Pharmaceuticals and Healthcare Report Q1 2011

Italy Pharmaceuticals and Healthcare Report Q1 2009

Italy Pharmaceuticals and Healthcare Report Q1 2010

Algeria Pharmaceuticals and Healthcare Report Q4 2010

Spain Pharmaceuticals and Healthcare Report Q4 2010

Spain Pharmaceuticals and Healthcare Report Q1 2011

Latvia Pharmaceuticals and Healthcare Report Q2 2010



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds